I’ve been reflecting on a recent case at my clinic, one that perfectly encapsulates the enigma that is IVF. A couple came to me after their first IVF cycle failed elsewhere. On paper, everything about their treatment seemed perfect – top-grade embryos, a receptive endometrium, and optimal hormonal levels. Yet, they didn’t achieve a pregnancy. As I sat with them, dissecting their cycle, I could see the frustration in their eyes. They were searching for answers, for a reason why their seemingly flawless cycle didn’t result in the baby they longed for. This scenario is not uncommon, and it underscores a harsh truth I’ve learned in my years as an IVF specialist: successful IVF treatments rarely make perfect sense.
One might think that with all the technological advancements in reproductive medicine, we should be able to predict outcomes with a high degree of certainty. However, the reality is far more complex. Biology, unlike engineering or data analytics, refuses to adhere to neat and predictable rules. In my experience, even when all the variables align perfectly, the outcome can still be disappointing. IVF, much like life itself, is a dance with unpredictability.
For those from analytical professions — engineers, programmers, analysts — this unpredictability is particularly unsettling. You’re accustomed to inputs leading to predictable outputs, and when that fails, there’s an innate drive to identify the bug and fix it. But, as I often remind my patients, biology is not software. It doesn’t always follow the logical pathways we are used to mapping out. In the world of reproductive medicine, a top-grade blastocyst doesn’t guarantee a baby any more than a promising startup guarantees success. The parallels between IVF and startups are striking, and I’ve written about this connection before in The Unseen Connection Between Risk in Startups and IVF Treatments.
Consider this: Even when studies show that a particular procedure or test should enhance success rates, individual biological variability often trumps theoretical models. For instance, the Endometrial Receptivity Assay (ERA) is a test designed to determine the best time for embryo transfer. On paper, it seems like a logical step to improve outcomes. However, in practice, its utility is debatable, and I’ve seen many patients undergo this test without any improvement in their success rates. It’s reminiscent of a startup pivoting based on market research, only to find that the real-world application doesn’t match the data-driven expectations. I explored this concept in detail in The Unexpected Parallel Between Startup Pivots and IVF Treatments.
What frustrates many patients is the barrage of tests and interventions that follow a failed cycle. It’s tempting to think that more data will provide clarity, but often, the opposite is true. More tests can lead to more confusion and anxiety, not less. We’re drawn to the allure of over-testing because it feels proactive, but in reality, it’s often a way to fill the void of uncertainty with activity. This is something I’ve seen time and again, and it’s a topic I’ve touched on in Why Transparent Discussions Make or Break Your IVF Journey.
At the Malpani Infertility Clinic, my focus is on honest, evidence-based guidance. I believe in empowering my patients with knowledge about what can and cannot be controlled. While many factors affect IVF success, there are still unknown elements that science has yet to unravel. We must acknowledge that while we can optimize many aspects of the treatment, we cannot guarantee success. It’s a humbling admission, but an essential one.
This brings me to a broader observation that applies not just to IVF but to many areas of life, including investing. We live in a world that craves certainty, yet the most meaningful endeavors are often those with the least predictable outcomes. Investing in startups, much like IVF, involves a leap of faith. You assess the parameters, make informed decisions, and hope for the best. But at the end of the day, both are subject to the whims of unpredictability. This is something I’ve reflected on in my post Why Every Successful IVF Cycle Reminds Me of a Winning Startup Pitch.
In conclusion, if there’s one lesson that both IVF and investing have taught me, it’s that success is rarely a straight line. It’s a journey filled with setbacks, learning, and occasional triumphs. And while the failures can be disheartening, they often pave the way for greater understanding and eventual success. As I often tell my patients, and as I remind myself in my investment ventures, patience and resilience are our greatest allies in the face of uncertainty.